文献速递糖尿病

TCF7L2基因多态性与1型糖尿病风险人群从单一到多重自身抗体阳性的进展

Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2018-10-01

研究纳入244例筛查时单一自身抗体阳性的1型糖尿病患者亲属,分析TCF7L2 rs4506565风险等位基因与进展至多重自身抗体阳性的关联。中位随访5.2年,62%进展为多重抗体阳性;整体无显著预测作用,但GAD65单一阳性携带者进展风险降低(HR 0.65,P=0.033),而IA-2或胰岛素抗体阳性且超重/肥胖者风险增加(HR 3.02,P=0.016)。

要点

  • TCF7L2风险等位基因对胰岛自身免疫进展的影响因抗体特异性而异。
  • GAD65单一阳性者携带风险等位基因进展风险降低(HR 0.65)。
  • IA-2或胰岛素抗体阳性且超重/肥胖者携带风险等位基因进展风险增加(HR 3.02)。

核心结论

  • 2型糖尿病相关TCF7L2位点影响胰岛自身免疫进展,效应因自身抗体特异性和超重/肥胖交互作用而异。

研究设计与样本

  • 研究纳入Type 1 Diabetes TrialNet Pathway to Prevention研究中244例筛查时单一自身抗体阳性且有Immunochip数据的1型糖尿病患者亲属,中位年龄12.8岁(范围1.2-45.9),47.5%男性,90.2%白人。

主要发现

  • 随访中位5.2年(范围0.2-12.6),62%的单一自身抗体阳性参与者进展为多重自身抗体阳性。
  • 整体队列中TCF7L2位点未显著预测进展至多重自身抗体阳性。
  • 在158例单一GAD65自身抗体阳性参与者中,携带≥1个风险等位基因者进展风险降低(HR 0.65,P=0.033),校正HLA风险单倍型和年龄后。
  • 在仅IA-2或胰岛素自身抗体阳性者中,携带≥1个TCF7L2风险等位基因整体不显著,但在超重或肥胖参与者中增加进展风险(HR 3.02,P=0.016),校正年龄后。

临床怎么用

  • 对单一自身抗体阳性的1型糖尿病亲属,可结合TCF7L2基因型和抗体特异性及体重状态评估进展风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The type 2 diabetes-associated alleles at the TCF7L2 locus mark a type 1 diabetes phenotype characterized by single islet autoantibody positivity as well as lower glucose and higher C-peptide measures. Here, we studied whether the TCF7L2 locus influences progression of islet autoimmunity, from single to multiple (≥2) autoantibody positivity, in relatives of patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: We evaluated 244 participants in the Type 1 Diabetes TrialNet Pathway to Prevention study with confirmed single autoantibody positivity at screening and Immunochip single nucleotide polymorphism data (47.5% male; median age 12.8 years, range 1.2-45.9; 90.2% white). We analyzed risk allele frequency at TCF7L2 rs4506565 (in linkage disequilibrium with rs7903146). Altogether, 62.6% participants carried ≥1 risk allele. Univariate and multivariable Cox proportional hazards models and Kaplan-Meier statistical methods were used. RESULTS: During follow-up (median 5.2 years, range 0.2-12.6), 62% of the single autoantibody-positive participants developed multiple autoantibody positivity. In the overall cohort, the TCF7L2 locus did not significantly predict progression to multiple autoantibody positivity. However, among single GAD65 autoantibody-positive participants (n = 158), those who carried ≥1 risk allele had a lower rate of progression to multiple autoantibody positivity (hazard ratio [HR] 0.65, P = 0.033) than those who did not, after adjustment for HLA risk haplotypes and age. Among subjects who were either IA-2 or insulin autoantibody positive only, carrying ≥1 TCF7L2 risk allele was not a significant factor overall, but in overweight or obese participants, it increased the risk of progression to multiple autoantibody positivity (HR 3.02, P = 0.016) even with adjustment for age. CONCLUSIONS: The type 2 diabetes-associated TCF7L2 locus influences progression of islet autoimmunity, with differential effects by autoantibody specificity and interaction by obesity/overweight.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Redondo MJ, Steck AK, Sosenko J, et al. Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes. Diabetes Care. 2018. PMID: 30275285. doi:10.2337/dc18-0861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。